Full Press Release Details
Inc. Receives NYSE American Notice
FL. (December 20, 2022) - Oragenics, Inc.
(NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious
diseases including COVID-19, today announced that it received a Notice (the "Notice") on December 19, 2022 from the
NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the continued listing standards
as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").
Notice stated that because the Company's common stock had been trading for a low price per share for a substantial period of time,
the Company was not in compliance with Section 1003(f)(v) of the Company Guide. The NYSE American staff determined that the Company's
continued listing is predicated on it demonstrating sustained price improvement within a reasonable period of time or effecting a reverse
stock split of its common stock, which the staff determined to be until June 19, 2023, and could be extended to the Company's next
annual meeting of shareholders to be held in 2023. The Company intends to seek to regain compliance with the NYSE American's continued
listing standards by undertaking a measure or measures that are considered necessary and in the best interests of the Company and its
Notice has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade
on the NYSE American under the symbol "OGEN" but will have an added designation of "BC" to indicate that the
Company is not in compliance with the NYSE American's listing standards. Additionally, the Notice does not result in the immediate
delisting of the Company's stock from the NYSE American. The Company's receipt of the Notice does not affect the Company's
business, operations or reporting requirements with the Securities and Exchange Commission. The Company is actively engaged in discussions
with the NYSE American and is developing plans to regain compliance with the NYSE American's continued listing standards within
the time period indicated.
Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant
organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The
NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National
Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration.
Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
For more information about Oragenics, please visit www.oragenics.com.
communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect," "anticipate," "intend,"
"estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties,
and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These
factors include, but are not limited to, the following: the Company's ability to advance the development of its vaccine candidate
and lantibiotics candidate under the timelines and in accord with the milestones it projects; the Company's ability to obtain funding,
non-dilutive or otherwise, for the development of the vaccine and lantibiotic product candidates, whether through its own cash on hand,
or another alternative source; the ability to regain compliance with NYSE American's continued listing standards and the impact
of dong so on financing; the regulatory application process, research and development stages, and future clinical data and analysis relating
to vaccines and lantibiotics, including any meetings, decisions by regulatory authorities, such as the FDA and investigational review
boards, whether favorable or unfavorable; the potential application of our vaccine candidate to variants and other coronaviruses; the
Company's ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the nature of competition
and development relating to COVID-19 immunization and therapeutic treatments and demand for vaccines and antibiotics; the Company's
expectations as to the outcome of preclinical studies, nasal administration, transmission, manufacturing, storage and distribution; other
potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, interruptions to manufacturers and
supply chains, adverse impacts on healthcare systems and disruption of the global economy; and general economic and market conditions
and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements
included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions
or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances
change, except as otherwise required by law.
Murphy, Chief Executive Officer